Skip to main content
. 2023 Aug 21;109(4):761–769. doi: 10.4269/ajtmh.23-0280

Table 1.

Classification of certainty of the diagnosis of primaquine-associated severe hemolysis

Probable
 Paired Hb* recorded
  Decrease in Hb to < 7 g/dL and > 25% fractional decrease
  Decrease in Hb to ≥ 5 g/dL
  Decrease in Hb to 3 to 4.99 g/dL or > 25% decrease AND dark-brown or red urine or jaundice or shortness of breath or heart failure   or blood transfusion or renal replacement therapy or death
 Single Hb recorded after PQ administration
  Hb < 7 g/dL AND dark, brown or red urine or jaundice AND shortness of breath or heart failure or blood transfusion or renal   replacement therapy or death
Possible
 No Hb recorded
  Dark urine or jaundice AND blood transfusion or renal replacement therapy or death
 Single Hb recorded after PQ administration
  Hb < 7 g/dL AND dark, brown, or red urine or jaundice or shortness of breath or heart failure or blood transfusion or renal   replacement therapy or death
  Hb ≥ 7 g/dL AND dark urine or jaundice AND shortness of breath or heart failure or blood transfusion or renal replacement therapy   or death
Uncertain
 Not fulfilling probable or possible criteria but considered serious PQ-associated hemolysis by authors

Hb = hemoglobin; PQ = primaquine.

*

Hemoglobin reported before and after PQ administration.

Hemoglobin reported only after PQ administration.

All cases required temporal association with PQ within the preceding 4 weeks.